Tests stopping beta-blockers in older adults with heart failure
Compares gradually stopping beta-blockers with continuing them in older adults with heart failure.
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- Pleasanton, United StatesSee the site
- Trial code
- Registry title
- Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 240 people, planned
- Started
- 2 Feb 2026
- Expected to end
- Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo (matching)
- Beta-blockers
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 or older with heart failure with preserved ejection fraction (HFpEF) who take a beta-blocker and are Kaiser Permanente Northern California members.
- Age
- 60 years or older
- Sex
- All sexes
- Disease stage
- Heart failure with preserved ejection fraction (EF 50% or higher on the latest echocardiogram), with a hospital stay for heart failure in the past 24 months or BNP above 100 pg/mL in the past 24 months. Must be able to walk and live outside hospital.
- Earlier treatment
- Must be taking atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.
- Biomarker or test result
- BNP above 100 pg/mL in the past 24 months (one of two ways to show heart failure).
Main reasons for not taking part
- Another cause of the HFpEF syndrome
- A strong reason to keep the beta-blocker, such as earlier EF below 50%, current angina, or a heart attack or coronary procedure within 3 years
- Hospital stay for atrial fibrillation or flutter with a fast heartbeat in the past 12 months
- Hospital stay mainly for heart failure in the past 30 days
- Dementia, life expectancy under 6 months, or unable to give informed consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Ambulatory adults age ≥60 years with HFpEF (EF ≥50% based on most recent transthoracic echocardiogram)
- Evidence of HF, defined by at least one of the following:; Hospitalized with HF in the past 24 months (defined by diagnostic codes in any position); BNP >100 pg/mL in the past 24 months
- Taking any of the following ß-blockers: atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate (i.e., pharmacy prescription data)
- Kaiser Permanente Northern California Membership
Who cannot take part
- Compelling guideline indication for ß-blocker:; Prior EF <50% (i.e., based on the structured data field on transthoracic echocardiogram); Current anginal symptoms (i.e., based on the Rose Angina single-question screener for angina); MI (i.e., diagnostic codes) and/or coronary revascularization (i.e., procedure codes) within 3 years; Hospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter with a rapid ventricular response in the prior 12 months (i.e., not for an elective procedure such as a cardioversion or an ablation); Other documented reason in the opinion of the treating provider and/or enrolling clinician-investigator
- Alternative etiologies of HFpEF syndrome
- Diagnosed dementia (i.e., diagnostic codes)
- Hospitalization for a primary discharge diagnosis of HF within the past 30 days
- Estimated life expectancy <6 months (i.e., diagnostic codes)
- Unable to provide informed consent
- Loss of Kaiser Permanente Northern California Membership
Where in United States
- Kaiser Permanente Northern California (KPNC)Pleasanton, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.
Read full original descriptionShow less
Participants will be randomly assigned to one of two groups:
Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.
Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.
All participants will:
* Take study medicine for about 4 months * Have their blood pressure and heart rate monitored * Complete regular phone calls and questionnaires about how they are feeling
This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
The 2 groups in the trial
- DeprescribePlacebo, for comparison
Participants will have their beta-blocker replaced with pills that have decreasing amounts of beta-blocker until they are completely off their medicine and taking placebo pills.
Treatment: Placebo (matching)
- ContinuationExisting treatment, for comparison
Participants will continue their beta-blocker at their usual dose in capsules that look identical to those used for the deprescribe arm.
Treatment: Beta-blockers
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Determining Evidence in a Placebo-Controlled, Randomized Experiment Studying Continuation vs. Removal of Inessential Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
- Plain-language title
- Tests stopping beta-blockers in older adults with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026